Literature DB >> 17846295

Differential protein kinase C isoform abundance in ascending aortic aneurysms from patients with bicuspid versus tricuspid aortic valves.

Jeffrey A Jones1, Robert E Stroud, Brooke S Kaplan, Allyson M Leone, Joseph E Bavaria, Joseph H Gorman, Robert C Gorman, John S Ikonomidis.   

Abstract

BACKGROUND: It is recognized that different events contribute to the initiation of ascending thoracic aortic aneurysms (ATAAs) in patients with bicuspid aortic valves (BAV) versus patients with tricuspid aortic valves (TAV), but the molecular signaling pathways driving aneurysm formation remain unclear. Protein kinase C (PKC) is a superfamily of kinases which differentially mediate signaling events that lead to altered gene expression and cellular function, and may regulate downstream mediators of vascular remodeling. The present study tested the hypothesis that ATAA development in patients with BAV versus TAV proceeds by independent signaling pathways involving differential PKC signaling. METHODS AND
RESULTS: ATAA samples were collected from BAV (n=57) and TAV (n=55) patients and assessed for 10 different PKC isoforms by immunoblotting. Results were expressed as a percent change in abundance (mean+/-SEM) from a nonaneurysmal control group (100%, n=21). Correlation analysis was performed, and relationships between PKC and matrix metalloproteinase abundance were reported. In the BAV group, classic and novel PKC isoforms (PKC-alpha, betaI, gamma, epsilon, theta) were increased, whereas PKC-eta and atypical PKC-zeta were decreased. In the TAV group, classic and novel isoforms were decreased and atypical PKC-zeta was elevated. Positive correlations between PKC and matrix metalloproteinase abundance were identified.
CONCLUSIONS: Differential PKC isoform abundance was observed in ATAA samples from patients with BAV versus TAV, suggesting independent molecular signaling pathways may be operative. Induction of independent transcriptional programs may result and may provide a mechanistic foundation for developing selective diagnostic/therapeutic strategies for patients with ATAAs secondary to BAV or TAV.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17846295     DOI: 10.1161/CIRCULATIONAHA.106.681361

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  6 in total

Review 1.  Molecular pathogenesis of genetic and sporadic aortic aneurysms and dissections.

Authors:  Ying H Shen; Scott A LeMaire
Journal:  Curr Probl Surg       Date:  2017-02-03       Impact factor: 1.909

Review 2.  A measured approach to managing the aortic root in patients with bicuspid aortic valve disease.

Authors:  Ismail El-Hamamsy; Magdi H Yacoub
Journal:  Curr Cardiol Rep       Date:  2009-03       Impact factor: 2.931

Review 3.  Common Chemical Inductors of Replication Stress:  Focus on Cell-Based Studies.

Authors:  Eva Vesela; Katarina Chroma; Zsofia Turi; Martin Mistrik
Journal:  Biomolecules       Date:  2017-02-21

4.  Deficiency of FAM3D (Family With Sequence Similarity 3, Member D), A Novel Chemokine, Attenuates Neutrophil Recruitment and Ameliorates Abdominal Aortic Aneurysm Development.

Authors:  Li He; Yi Fu; Jingna Deng; Yicong Shen; Yingbao Wang; Fang Yu; Nan Xie; Zhongjiang Chen; Tianpei Hong; Xinjian Peng; Qingqing Li; Jing Zhou; Jingyan Han; Ying Wang; Jianzhong Xi; Wei Kong
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-05-31       Impact factor: 8.311

5.  Bicuspid Aortic Valve Alters Aortic Protein Expression Profile in Neonatal Coarctation Patients.

Authors:  Katie L Skeffington; Andrew R Bond; Safa Abdul-Ghani; Dominga Iacobazzi; Sok-Leng Kang; Kate J Heesom; Marieangela C Wilson; Mohamed Ghorbel; Serban Stoica; Robin Martin; M Saadeh Suleiman; Massimo Caputo
Journal:  J Clin Med       Date:  2019-04-16       Impact factor: 4.241

6.  Analysis of extracellular superoxide dismutase and Akt in ascending aortic aneurysm with tricuspid or bicuspid aortic valve.

Authors:  A Arcucci; M R Ruocco; F Albano; G Granato; V Romano; G Corso; C Bancone; E De Vendittis; A Della Corte; S Montagnani
Journal:  Eur J Histochem       Date:  2014-07-18       Impact factor: 3.188

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.